Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer Tanya Dorff , Lisa G. Horvath , Karen Autio , Alice Bernard-Tessier , Matthew B. Rettig , Jean-Pascal Machiels , Mehmet A. Bilen , Martijn P. Lolkema , Nabil Adra , Sylvie Rottey , Richard Greil , Nobuaki Matsubara , Daniel S.W. Tan , Alvin Wong , Hiroji Uemura , Charlotte Lemech , Johannes Meran , Youfei Yu , Mukul Minocha , Mason McComb , Hweixian Leong Penny , Vinita Gupta , Xuguang Hu , Gabor Jurida , Hosein Kouros-Mehr , Margit M. Janát-Amsbury , Tobias Eggert , Ben Tran crossref（2024）
摘要
Acapatamab-induced PSA response in patients who received prior lutetium-PSMA therapy
更多 查看译文
AI 理解论文
溯源树
样例
